Coronavirus disease (COVID-19)
Drug research and approvals for coronavirus disease (COVID-19): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 274 studies of coronavirus disease (COVID-19) are recruiting on ClinicalTrials.gov, Health Canada has authorized 140 drug trials for it since 2013, and the EU has 12 authorised medicines for it.
- Recruiting worldwide: 274
- Trials authorized in Canada: 140
- FDA orphan approvals: 0
- EU medicines: 12
Recruiting Now
Newest start dates first, of 274 recruiting on ClinicalTrials.gov ↗- Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant…NCT07890454 · Phase 3 · Sanofi · starts Oct 28, 2026
- SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID DysfunctionNCT07597902 · Phase 2 · Icahn School of Medicine at Mount Sinai · starts Oct 20, 2026
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsNCT07863635 · Phase 4 · ModernaTX, Inc. · starts Oct 9, 2026
- Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility StudyNCT07874217 · Not applicable · Oxford Brookes University · starts Oct 5, 2026
- Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional…NCT07149428 · Not reported · National Institute on Deafness and Other Communication Disorders (NIDCD) · starts Oct 1, 2026
- A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to…NCT07743580 · Phase 3 · Shionogi · starts Sep 14, 2026
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years…NCT07808697 · Phase 2 · ModernaTX, Inc. · starts Sep 4, 2026
- CEDRN Pandemic Preparedness RegistryNCT07933861 · Not reported · University of British Columbia · starts Sep 1, 2026
- A Study of COVID-19 Vaccine(s) in Children and AdultsNCT07798648 · Phase 3 · BioNTech SE · starts Aug 31, 2026
- Micro-choice-based Intervention for Multicausal FatigueNCT07726082 · Not applicable · University Hospital, Basel, Switzerland · starts Aug 13, 2026
Trials Authorized in Canada
The 10 newest of 140; search them all in Canada trials| May 15, 2025 | An interventional efficacy and safety, phase 3, randomized, double-blind, 3-arm study to investigate ibuzatrelvir in adults with symptomatic COVID-19 who are…IBUZATRELVIR (PF-07817883) / REMDESIVIR | Pfizer | Pending |
| Feb 25, 2025 | Adaptive platform trial of treatments for respiratory infections in community settings (treatresp)BALOXAVIR MARBOXIL / OSELTAMIVIR | UNITY HEALTH TORONTO | Ongoing |
| Feb 17, 2025 | An interventional efficacy and safety, phase 3, double-blind, 2-arm study to investigate orally administered ibuzatrelvir compared with placebo in…IBUZATRELVIR (PF-07817883) | Pfizer | Ongoing |
| Aug 23, 2024 | Antiviral strategies in the prevention of long-term cardiovascular outcomes following COVID-19: the paxlovid/remdesivir effectiveness for the prevention of…NIRMATRELVIR / RITONAVIR / REMDESIVIR | SINAI HEALTH SYSTEM | Pending |
| Jun 5, 2024 | Phase 1/2 study to evaluate safety and immunogenicity of a prophylactic plasmid dna booster vaccine against sars-cov- -002] in generally healthy adults 18…COVIGENIX VAX-002 | ENTOS PHARMACEUTICALS | Ongoing |
| Apr 18, 2024 | A phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humansCHAD-COV/MAC | MCMASTER UNIVERSITY | Ongoing |
| Nov 22, 2023 | A phase 3, randomized, observer- blind, active- control study to evaluate the safety, reactogenicity, and immunogenicity of mrna- 1083 (sars- cov-2 and…MRNA-1083 / SPIKEVAX XBB.1.5 / FLUZONE HIGH-DOSE QUADRIVALENT / FLUARIX… | MODERNATX, INC. | Pending |
| Aug 22, 2023 | A double-blind, randomized, placebo-controlled, adaptive phase 2/3 study of the efficacy of lau-7b in the treatment of adults with long covid and moderate to…FENRETINIDE (LAU-7B) | LAURENT PHARMACEUTICALS | Closed |
| Aug 22, 2023 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of gs-5245 for the treatment of COVID-19 in nonhospitalized…OBELDESIVIR (GS-5245) | Gilead Sciences | Closed |
| May 24, 2023 | A phase I/iii randomized, double-blind study to evaluate the safety and neutralizing activity of azd5156/azd3152 for pre-exposure prophylaxis of COVID-19 in…AZD3152 / AZD7442 (AZD 1061 + AZD8895) | AstraZeneca Pharmaceuticals LP | Ongoing |
Medicines Authorised in the EU
Newest first| Sep 18, 2026 | Zokoveaensitrelvir | Shionogi B.V. | EMA ↗ |
| Apr 20, 2026 | mCombriaxinfluenza mRNA vaccine;COVID-19 mRNA vaccine | Moderna Biotech Spain, S.L. | EMA ↗ |
| Feb 12, 2026 | mNexspikeCOVID-19 mRNA vaccine | Moderna Biotech Spain, S.L. | EMA ↗ |
| Feb 12, 2025 | Kostaivezapomeran | Arcturus Therapeutics Europe B.V. | EMA ↗ |
| Jan 20, 2025 | Kavigalesipavibart | AstraZeneca AB | EMA ↗ |
| Mar 30, 2023 | BimervaxCOVID-19 Vaccine (recombinant, adjuvanted) | Hipra Human Health S.L. | EMA ↗ |
| Jan 28, 2022 | Paxlovidnirmatrelvir;ritonavir | Pfizer Europe MA EEIG | EMA ↗ |
| Dec 20, 2021 | NuvaxovidCOVID-19 Vaccine (recombinant, adjuvanted) | Sanofi Winthrop Industrie | EMA ↗ |
| Jan 6, 2021 | Spikevax (previously COVID-19 Vaccine Moderna)COVID-19 mRNA vaccine | Moderna Biotech Spain, S.L. | EMA ↗ |
| Dec 21, 2020 | ComirnatyCOVID-19 mRNA vaccine | BioNTech Manufacturing GmbH | EMA ↗ |
| Jul 3, 2020 | Vekluryremdesivir | Gilead Sciences Ireland UC | EMA ↗ |
| Mar 8, 2002 | Kineretanakinra | Swedish Orphan Biovitrum AB (publ) | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA